Section Arrow
Quote
PHAR.NASDAQ
- Pharming Group NV
Quotes are at least 15-min delayed:2025/04/12 04:14 EDT
Last
 8.05
-0.04 (-0.49%)
Day High 
8.1 
Prev. Close
8.09 
1-M High
9.1773 
Volume 
2.31K 
Bid
7.25
Ask
8.2
Day Low
7.79 
Open
7.79 
1-M Low
7.5018 
Market Cap 
553.30M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 8.12 
20-SMA 8.46 
50-SMA 8.61 
52-W High 11.07 
52-W Low 6.65 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.18/-0.00
Enterprise Value
658.42M
Balance Sheet
Book Value Per Share
3.23
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
297.20M
Operating Revenue Per Share
3.20
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals5.76+1.25+27.72%-- 
THTXTheratechnologies1.94+0.61+45.86%-- 
CDTConduit Pharmaceuticals Inc0.9101-0.1599-14.94%-- 
PRTGPortage Biotech Inc8.59+3.49+68.43%0.17PE
HEPAHepion Pharmaceuticals0.422-0.0091-2.11%-- 
Quotes are at least 15-min delayed：2025/04/12 04:14 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Pharming Group is a biopharmaceutical company. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-moleculekinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome. In addition, the firm's development pipeline includes KL1333, a potential first-in-disease asset for mitochondrial DNA-driven primary mitochondrial diseases. The company's reportable segments are RUCONEST, which derives maximum revenue, Joenja, U.S., and Europe and the Rest of the World (RoW). Geographically, it derives maximum revenue from the United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.